KMT2A and acute myeloid leukemia: For 11q23/KMT2A‐rearranged AML pediatric patients with FAB‐M5 morphology, patients with t(9;11)(p22;q23) demonstrated improved outcomes compared to those with other 11q23/KMT2A rearrangements.